The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
The endocannabinoid system in obesity and type 2 diabetes
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“ECs are produced following an elevation of intracellular Ca levels, and are inactivated when paracrine or autocrine cannabinoid receptor activation is to be terminated [8, 9].”
BackgroundLeptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559 · cited 4×
“To avoid excessive lipid accumulation in adipocytes, these mechanisms are normally subject to autocrine regulation in mature adipocytes, which limits both EC and CB1 levels through various mediators, including (1) leptin, which reduces EC levels in these cells [23], as also observed in the hypothalamus [18]; (2) PPAR-…”
BackgroundInfluentialVan Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,499
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · cited 1×
“The RIO-Lipids trial specifically examined the effects of rimonabant on metabolic risk factors, including adiponectin levels [72].”
BackgroundPi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & RIO-North America Study Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.7.761 · Cited by 1,218
Cota, D., Marsicano, G., Tschöp, M., Grübler, Y., Flachskamm, C., Schubert, M., Auer, D., Yassouridis, A., Thöne-Reineke, C., Ortmann, S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17725 · Cited by 1,168
Osei-Hyiaman, D., DePetrillo, M., Pacher, P., Liu, J., Radaeva, S., Bátkai, S., Harvey-White, J., Mackie, K., Offertáler, L., Wang, L., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523057 · Cited by 1,101
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 1×
“The data have been subject to different interpretations [78, 80], but clearly point to depressive disorders, nausea, anxiety and dizziness as the most frequent side effects leading to discontinuation.”
BackgroundThe endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Self-citation
Cited by
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
“Evidence showing that the endocannabinoid system is chronically activated in obese individuals and interacts with several major players in the multiple cascades of metabolic regulation has been reviewed elsewhere (121, 494).”
BackgroundInfluentialMarine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance
Calder, P. C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.08.010 · Cited by 1,717
Omega‐3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?
Calder, P. C. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04374.x · Cited by 1,347
β‐caryophyllene and β‐caryophyllene oxide—natural compounds of anticancer and analgesic properties
Fidyt, K., Fiedorowicz, A., Strządała, L., & Szumny, A. (2016) · Cancer Medicine · doi:10.1002/cam4.816 · Cited by 674
The Endocannabinoid System in Energy Homeostasis and the Etiopathology of Metabolic Disorders
Silvestri, C., & Di Marzo, V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.001 · Cited by 543
Self-citationLigresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Self-citationTam, J., Vemuri, V. K., Liu, J., Bátkai, S., Mukhopadhyay, B., Godlewski, G., Osei-Hyiaman, D., Ohnuma, S., Ambudkar, S. V., Pickel, J., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42551 · Cited by 454
Heyman, E., Gamelin, F.-X., Goekint, M., Piscitelli, F., Roelands, B., Leclair, E., Di Marzo, V., & Meeusen, R. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.09.017 · Cited by 427
“Hence, unlike the elevation of plasma AEA levels, which is likely to stimulate CB1 receptors with anti-lipolytic activity (Di Marzo, 2008), the increases in OEA and PEA levels might produce the opposite effect via PPAR-a.”
Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes
Ahrén, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2782 · Cited by 419
Is lipid signaling through cannabinoid 2 receptors part of a protective system?
Pacher, P., & Mechoulam, R. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.01.001 · Cited by 414
Modulating the endocannabinoid system in human health and disease – successes and failures
Pacher, P., & Kunos, G. (2013) · The FEBS Journal · doi:10.1111/febs.12260 · Cited by 405
Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics
He, M., & Shi, B. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0183-1 · Cited by 336
Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies
Maccarrone, M., Guzmán, M., Mackie, K., Doherty, P., & Harkany, T. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3846 · Cited by 298
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
Peng, J., Fan, M., An, C., Ni, F., Huang, W., & Luo, J. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13710 · Cited by 282
Taschler, U., Radner, F. P. W., Heier, C., Schreiber, R., Schweiger, M., Schoiswohl, G., Preiss-Landl, K., Jaeger, D., Reiter, B., Koefeler, H. C., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.215434 · Cited by 282
Moreira, F. A., Grieb, M., & Lutz, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.003 · Cited by 272
Bíró, T., Tóth, B. I., Haskó, G., Paus, R., & Pacher, P. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.05.004 · Cited by 271
Jadoon, K. A., Ratcliffe, S. H., Barrett, D. A., Thomas, E. L., Stott, C., Bell, J. D., O’Sullivan, S. E., & Tan, G. D. (2016) · Diabetes Care · doi:10.2337/dc16-0650 · Cited by 262
Cannabinoids and appetite: food craving and food pleasure
Kirkham, T. C. (2009) · International Review of Psychiatry · doi:10.1080/09540260902782810 · Cited by 189
“Nevertheless, there is some evidence for deviation in endocannabinoid function in relation to obesity and other disorders of appetite (Matias, Cristino, & di Marzo, 2008).”
Background
Metadata
- Authors
- Di Marzo, V.
- Venue
- Diabetologia
- Published
- 2008-06-18
- Volume
- 51
- Issue
- 8
- Pages
- 1356-1367
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2136608474
- Cited by
- 281
- References
- 80
- FWCI
- 19.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.